Inventage Labs (CEO Joohee Kim), a company specializing in drug delivery system (DDS) platforms, announced on the 28th that it had unveiled its new platform, 'IVL-BioFluidic™', on a global stage at the 'Partnership Opportunities in Drug Delivery (PODD) 2025', a global drug delivery system conference held in Boston, USA on the 27th and 28th (local time).
PODD 2025 is a conference specializing in drug delivery systems, bringing together C-level executives, R&D, and business development (BD) experts from global pharmaceutical and biotech companies. It's an international event where the latest technologies and industry trends are shared. At the event, Inventage Lab presented on the topic, "Development and Application of Microfluidic Technology-Based Drug Delivery System Platforms," showcasing its new DDS platform.
'IVL-BioFluidic™' is a technology that supports the conversion of biopharmaceuticals such as antibodies and ADCs into subcutaneous (SC) formulations, based on the microfluidic-based DDS technology developed by Inventage Labs. The platform addresses the issues of increased viscosity and injection limitations that arise during high-dose antibody formulations, enabling the conversion of existing intravenous (IV)-based treatments to SC formulations. Notably, it boasts technological differentiation and commercial competitiveness by enabling high-dose SC formulations without the need for additional ingredients like hyaluronidase, which are typically used in conventional formulation development.
During this announcement period, Inventage Labs held numerous business meetings with major global pharmaceutical companies, including J&J, Roche, AstraZeneca, Gilead, Boehringer Ingelheim, and Takeda, discussing technological collaborations, joint development, and licensing opportunities. The company sees this announcement as an opportunity to showcase the scalability and uniqueness of its DDS platform to the global market.
Inventage Labs plans to use this PODD announcement as a catalyst for its global expansion. At CPhI Frankfurt 2025, held in Frankfurt, Germany, from October 28th to 30th, the company will discuss establishing a European GMP production base. At BIO Europe 2025, held in Vienna, Austria, from November 3rd to 5th, the company plans to continue discussions on new collaborations and technology transfers with global pharmaceutical companies.
Kim Joo-hee, CEO of Inventage Lab, said, “Through PODD, we were able to officially introduce the microfluidic-based platform technology we have accumulated over the years to the global industry and begin discussions on cooperation with major partners.” She added, “IVL-BioFluidic™ is a key technology that expands the company’s platform portfolio, and we will strengthen our technological competitiveness and corporate value by expanding into the biopharmaceutical field.”
- See more related articles
You must be logged in to post a comment.